Alireza Mohammad Mohammadi, MD
Neurological Surgery · Cleveland, OHNPI 1811293459
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Monteris Medical Corporation accounts for 72.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $2,722 and has fallen 98.0% since, to $55 in 2025.
Across 23 payments — averaging $179.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Monteris Medical Corporation$3K
- Steris Corporation$1K
- Varian Medical Systems, Inc.$74
- Stryker$55
Across 24 payments — averaging $2888.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Monteris Medical Corporation$69K
What the payments were for
- Consulting fees$1,00024%
- Speaking & faculty fees$1,50036%
- Travel & lodging$71017%
- Food & beverage$91022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Monteris Medical Corporation | 20 | $2,992 |
| Steris Corporation | 1 | $1,000 |
| Varian Medical Systems, Inc. | 1 | $74 |
| Stryker | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Neuroblate$2,445
- ORLocate$1,000
How this compares
$4,120 in reported general payments places this provider in the 55th percentile of 301 neurological surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 29 | $215 |
| Famotidine | 19 | $39 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Cleveland
- Abdi MohitCleveland$884K
- Mark BainCleveland$242K
- Pablo RecinosCleveland$211K
- Michael SteinmetzCleveland$168K
- Josue Avecillas ChasinCleveland$144K
- Gene BarnettCleveland$135K
- Prakash KotagalCleveland$82K
- Ajit KrishnaneyCleveland$76K
- Gabriel SmithCleveland$72K
- Peter RasmussenCleveland$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.